Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome
Cumali Efe(Medizinische Hochschule Hannover), Staffan Wåhlin(Karolinska University Hospital), Janett Fischer(Leipzig University), Hirsh D. Trivedi(Beth Israel Deaconess Medical Center), Alexandra Heurgué–Berlot(Inserm), Fredrik Rorsman(Uppsala University Hospital), Emma Nilsson(Skåne University Hospital), Luigi Muratori(University of Bologna), Nurhan Demir(Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi), Thomas D. Schiano(Icahn School of Medicine at Mount Sinai), Benedetta Terziroli Beretta‐Piccoli(Ente Ospedaliero Cantonale), Ellina Lytvyak(University of Alberta), Ida Henriksson(Örebro University), Murat Kıyıcı(Bursa Uludağ Üni̇versi̇tesi̇), Kristina Önnerhag(Skåne University Hospital), Eric M. Yoshida(Vancouver General Hospital), Alan Bonder(Beth Israel Deaconess Medical Center), Claudia Coppo(University of Bologna), Fatema Alalkim(University of British Columbia), Hanns–Ulrich Marschall(University of Padua), Thomas Berg(Leipzig University of Applied Sciences), Murat Torğutalp(Charité - Universitätsmedizin Berlin), David Semela(Kantonsspital St. Gallen), Ersan Özaslan(Ankara Numune Eğitim ve Araştırma Hastanesi), Fatih Eren(Bursa Uludağ Üni̇versi̇tesi̇), Paolo Muratori(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Mårten Werner(Umeå University), Aldo J. Montaño‐Loza(University of Alberta), Tuğrul Pürnak(Hacettepe University), Maneerat Chayanupatkul(Chulalongkorn University)
Cited by 68
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
|Gastroenterology|2017|929
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877